Search Results - "Brennan, Paul N"

Cell therapy for advanced liver diseases: Repair or rebuild by Dwyer, Benjamin J., Macmillan, Mark T., Brennan, Paul N., Forbes, Stuart J.

“…Advanced liver disease presents a significant worldwide health and economic burden and accounts for 3.5% of global mortality. When liver disease progresses to…”
Get full text

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT by Lee, Jeremy, Byrne, Christopher J., Brennan, Paul N., MacPherson, Iain, Dow, Eleanor, Dillon, John F.

“…Early diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), especially with advanced fibrosis, is crucial due to the increased risk of…”
Get full text

Integrating social nutrition principles into the treatment of steatotic liver disease by Ivancovsky-Wajcman, Dana, Brennan, Paul N., Kopka, Christopher J., Zelber-Sagi, Shira, Younossi, Zobair M., Allen, Alina M., Flórez, Karen R., Lazarus, Jeffrey V.

“…Current treatment of metabolic dysfunction-associated steatotic liver disease focuses on adjusting patients’ lifestyles, including promoting weight loss and…”
Get full text

Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks? by Brennan, Paul N., Dillon, John F., Tapper, Elliot B.

“…Gamma‐Glutamyl Transferase (γGT) is a key transferase involved in the transpeptidation of functional gamma‐glutamyl groups to various receptor moieties. It…”
Get full text

Effect of COVID-19 on presentations of decompensated liver disease in Scotland by Manship, Thomas, Brennan, Paul N, Campbell, Iona, Campbell, Stewart, Clouston, Thomas, Dillon, John F, Forrest, Ewan, Fraser, Andrew, Goh, Tee Lin, Johnston, Michael, Khan, Muhammad I, Livie, Victoria, Murray, Iain A, Saunders, Jayne, Troland, Debbie, Simpson, Ken J

“…Background and aimsSARS-CoV-2 and consequent pandemic has presented unique challenges. Beyond the direct COVID-related mortality in those with liver disease,…”
Get full text

Letter to the Editor: Future-proofing transplant hepatology training: Shared learnings from "across the pond" by Li, Wenhao, Brennan, Paul N, Tavabie, Oliver D

Get full text

Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD by Clare, Kathleen, Dillon, John F., Brennan, Paul N.

“…The pathogenesis of metabolic-associated fatty liver disease (MAFLD) is complex and thought to be dependent on multiple parallel hits on a background of…”
Get full text

Systematic review: the role of frailty in advanced chronic liver disease by Bowers, Sarah P, Brennan, Paul N, Dillon, John F

“…Frailty is a known predictor of outcome and mortality in patients undergoing liver transplantation. However, most patients remain unsuitable transplant…”
Get full text

We must address the MASLD awareness gap, improve educational quality and prepare for the digitally quantified self by Kopka, Christopher J., Pugliese, Nicola, Brennan, Paul N., Lazarus, Jeffrey V.

Get full text

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach by Brennan, Paul N., Elsharkawy, Ahmed M., Kendall, Timothy J., Loomba, Rohit, Mann, Derek A., Fallowfield, Jonathan A.

“…Nonalcoholic steatohepatitis (NASH) might soon become the leading cause of end-stage liver disease and indication for liver transplantation worldwide. Fibrosis…”
Get full text

Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm by Brennan, Paul N, Zelber-Sagi, Shira, Allen, Alina M, Dillon, John F, Lazarus, Jeffrey V

Get more information

Decentralisation of hepatitis C virus care into community settings: A key approach on the path to elimination by Brennan, Paul N., Byrne, Christopher J., Dillon, John F.

Get full text

Opportunities and challenges following approval of resmetirom for MASH liver disease by Lazarus, Jeffrey V, Ivancovsky Wajcman, Dana, Mark, Henry E, Younossi, Zobair M, Kopka, Christopher J, Cohen, Nevin, Bansal, Meena B, Betel, Michael, Brennan, Paul N

Get full text

New horizons in hepatitis B and C in the older adult by Kemp, Linda, Clare, Kathleen E, Brennan, Paul N, Dillon, John F

“…Abstract Hepatitis C (HCV) and hepatitis B (HBV), are blood-borne viruses that can cause acute hepatitis; but are clinically relevant because chronic infection…”
Get full text

A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease by Ivancovsky Wajcman, Dana, Byrne, Christopher J, Dillon, John F, Brennan, Paul N, Villota-Rivas, Marcela, Younossi, Zobair M, Allen, Alina M, Crespo, Javier, Gerber, Lynn H, Lazarus, Jeffrey V

“…Metabolic dysfunction-associated steatotic liver disease (MASLD) management guidelines have been published worldwide; we aimed to summarize, categorize and…”
Get full text

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI) by Brennan, Paul N, Cartlidge, Peter, Manship, Thomas, Dillon, John F

“…The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here,…”
Get full text

Hepatitis B, Hepatitis C and Liver Disease: A Review for the Dental Practitioner by Macpherson, Iain, Brennan, Paul N, Dillon, John F

“…The prevalence of chronic liver disease continues to rise, and important causes include viral infections, such as hepatitis B and hepatitis C. Both of these…”
Get full text

Letter: acute liver failure of indeterminate aetiology—Authors’ reply by Brennan, Paul N., Donnelly, Mhairi C., Simpson, Kenneth J.

“…Linked ContentThis article is linked to Brennan et al and Fujiwara et al papers. To view these articles visit https://doi.org/10.1111/apt.14566 and…”
Get full text

Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis by Brennan, Paul N, Dillon, John F, McCrimmon, Rory

“…Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. A number of treatment agents…”
Get full text

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group by McPherson, Stuart, Armstrong, Matthew J, Cobbold, Jeremy F, Corless, Lynsey, Anstee, Quentin M, Aspinall, Richard J, Barclay, Stephen T, Brennan, Paul N, Cacciottolo, Tessa M, Goldin, Robert D, Hallsworth, Kate, Hebditch, Vanessa, Jack, Kathryn, Jarvis, Helen, Johnson, Jill, Li, Wenhao, Mansour, Dina, McCallum, Mary, Mukhopadhya, Ashis, Parker, Richard, Ross, Valerie, Rowe, Ian A, Srivastava, Ankur, Thiagarajan, Prarthana, Thompson, Alexandra I, Tomlinson, Jeremy, Tsochatzis, Emmanuel A, Yeoman, Andrew, Alazawi, William

“…Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the general population. The evidence base for the investigation and…”
Get more information